The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC).
 
Silvia Damian
Employment - Biofarma Group (I)
Leadership - Biofarma Group (I)
Research Funding - Amgen (Inst); Incyte (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
Matteo Simonelli
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Incyte; Naya Oncology; SERVIER
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Roche; Sanofi
 
Krisztian Homicsko
Research Funding - BMS Global; MSD; Owkin (Inst); ROCHE; TOLREMO
 
Ilaria Colombo
Employment - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE; GlaxoSmithKline (Inst); Incyte (Inst); MSD Oncology (Inst)
Speakers' Bureau - Abbvie (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst)
Research Funding - Incyte (Inst); Merck KGaA (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst); Orion Clinical (Inst); Tolremo (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Philippe Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Maikel van der Velden
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Elisabeth Richards
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Michelle Kinder
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Qingyang Liu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Edward Wang
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin; Loxo/Lilly (Inst); Merck KGaA; MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)